Alnylam and Takeda Form Alliance In RNAi

I’ll admit, I’m an RNAi hater, but more on that later. Alnylam and Takeda announced today that they have formed an alliance in RNAi therapeutics covering the fields of oncology and metabolic disease. Here are the deal details:

Takeda becomes Alnylam’s strategic partner for RNAi therapeutics over a five-year period
$150M in upfront and near [...]

Sucampo and Takeda’s Amitiza Approved for IBS-c

On a disease sexiness scale from 0-100, chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS-c) are close to rounding out the bottom of that range however, they remain important medical problems. CIC accounts for roughly 6 million related outpatient visits each year and just over a quarter million hospital admissions with constipation as [...]

Takeda Buys Millennium: Update

The market responded to the aforementioned acquisition news yesterday by penalizing Takeda 2%, even after the announcement it would also buy back a significant number of its own shares. The move comes as company fights to lessen the impact of projected revenue lost by the patent expirations of Prevacid and Actos in 2010 and [...]

Takeda Buys Millennium for $8.8 billion

Takeda, a Japanese pharmaceutical giant, purchased Millennium Pharmaceuticals this morning for $8.8B or $25.00/share which works out to be an $8.61/share, 53% premium over Millennium’s share price of $16.38 yesterday. The move by Takeda comes less than three months after a chief Japanese rival firm, Eisai, purchased US based MGI Pharma and it’s strong [...]

Top Biopharma Deals Q1 ‘08

It’s a just a quarter of the way into 2008 and it is clear the both large
biotech and pharma have holes to fill in thier pipeline. Six deals have
already been inked that total over a half a billion bio-dollars each.
Below are 4 of the top deals thus far:
Genzyme/Isis ($1,900M) - Genzyme paid Isis $175M in
cash [...]